drugset / Trial / NCT06305780

RECOVER-AUTONOMIC Platform Protocol

NCT06305780

Phase 2 Completed 381 enrolled Kanecia Obie Zimmerman
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

Timeline

Start
2024-03-11
Primary completion
2025-07-09
Completion
2025-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic
Subject Ivabradine Small molecule Oral

Indications